Kronos Bio/KRON

$1.01

-1.94%
-
1D1W1MYTD1YMAX

About Kronos Bio

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.

Ticker

KRON

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Norbert Bischofberger

Employees

62

Headquarters

San mateo, United States

Kronos Bio Metrics

BasicAdvanced
$62.5M
Market cap
-
P/E ratio
-$1.95
EPS
1.85
Beta
-
Dividend rate
$62.5M
1.84951
$2.29
$0.73
277.44K
7.239
-44.34%
-55.84%
-48.77%
9.939
0.385
0.393
17.69%

What the Analysts think about Kronos Bio

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 2 analysts.
320.79% upside
High $6.00
Low $2.50
$1.01
Current price
$4.25
Average price target

Kronos Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,150% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2.2M
144.44%
Net income
$-25.3M
-19.17%
Profit margin
-1,150%
-66.93%

Kronos Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 18.1%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.46
-$0.52
-$0.54
-$0.43
-
Expected
-$0.45
-$0.46
-$0.51
-$0.53
-$0.41
Surprise
3.37%
13.04%
5.37%
-18.1%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Kronos Bio stock?

Kronos Bio (KRON) has a market cap of $61.9M as of April 20, 2024.

What is the P/E ratio for Kronos Bio stock?

The price to earnings (P/E) ratio for Kronos Bio (KRON) stock is 0 as of April 20, 2024.

Does Kronos Bio stock pay dividends?

No, Kronos Bio (KRON) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Kronos Bio dividend payment date?

Kronos Bio (KRON) stock does not pay dividends to its shareholders.

What is the beta indicator for Kronos Bio?

Kronos Bio (KRON) has a beta rating of 1.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Kronos Bio stock price target?

The target price for Kronos Bio (KRON) stock is $4.25, which is 320.79% above the current price of $1.01. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Kronos Bio stock

Buy or sell Kronos Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing